170 related articles for article (PubMed ID: 36627149)
1. Daratumumab for the treatment of refractory ANCA-associated vasculitis.
Ostendorf L; Burns M; Wagner DL; Enghard P; Amann K; Mei H; Eckardt KU; Seelow E; Schreiber A
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36627149
[No Abstract] [Full Text] [Related]
2. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
3. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
4. ANCA-Associated Vasculitis: Core Curriculum 2020.
Geetha D; Jefferson JA
Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
[TBL] [Abstract][Full Text] [Related]
5. The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature.
Delvino P; Monti S; Balduzzi S; Belliato M; Montecucco C; Caporali R
Rheumatol Int; 2019 Feb; 39(2):367-375. PubMed ID: 30074077
[TBL] [Abstract][Full Text] [Related]
6. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
Eriksson P
J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
8. The use of ECMO in pediatric granulomatosis with polyangiitis.
Finkel R; Honig J; Chao CP; Rescoe E; Solomon S
Pediatr Rheumatol Online J; 2022 May; 20(1):35. PubMed ID: 35538584
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society.
Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Okada M; Kunimoto Y; Watanabe T; Inagaki A; Yoshida T; Imaizumi M; Nakamura T; Matsunobu T; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T
Auris Nasus Larynx; 2021 Feb; 48(1):2-14. PubMed ID: 32768313
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Gulati K; Edwards H; Prendecki M; Cairns TD; Condon M; Galliford J; Griffith M; Levy JB; Tam FWK; Tanna A; Pusey CD; McAdoo SP
Kidney Int; 2021 Dec; 100(6):1316-1324. PubMed ID: 34560140
[TBL] [Abstract][Full Text] [Related]
11. [A preliminary study of the significance of autoantibodies against light chain of myeloperoxidase on pulmonary damages in myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
Zhang L; Shuai Z; Hu Z; Zhang M; Chen S
Zhonghua Nei Ke Za Zhi; 2015 Jun; 54(6):511-6. PubMed ID: 26359012
[TBL] [Abstract][Full Text] [Related]
12. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Jones RB; Ferraro AJ; Chaudhry AN; Brogan P; Salama AD; Smith KG; Savage CO; Jayne DR
Arthritis Rheum; 2009 Jul; 60(7):2156-68. PubMed ID: 19565480
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
15. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
17. [The clinical analysis of 46 cases with antineutrophil cytoplasmic antibody-associated vasculitis].
Zhang Q; Zhou HQ; Li YH; Guo J; Xu PH; Lu MH; Liu XL; Wang L; Li SG
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(27):2146-9. PubMed ID: 27464538
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
19. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.
Roccatello D; Sciascia S; Murgia S; Quattrocchio G; Ferro M; De Simone E; Naretto C; Barreca A; Sammartino A; Rossi D; Fenoglio R
Front Immunol; 2022; 13():777134. PubMed ID: 35401565
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
